CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset

MPT-062Positive
AI Analysis

Summary

Matchpoint secured $150M in Series B funding backed by major pharmaceutical companies to advance MPT-062, an oral T cell modulator, into clinical development for autoimmune and inflammatory conditions in 2027.

Importance:6/10
Sentiment:
0.70
series_b_fundingoral_drugt_cell_modulatorautoimmuneinflammatory_conditions

Read the original article

Published by BioSpace on October 8, 2026 1:04 PM

Read Original